Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Venetoclax in Combination With Pembrolizumab in Subjects With Previously Untreated NSCLC Whose Tumors Have High PD-L1 Expression

NCT04274907 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04274907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04274907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Venetoclax in Combination With Pembrolizumab in Subjects With Previously Untreated NSCLC Whose Tumors Have High PD-L1 Expression
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2020
Completion date
February 2, 2021
Enrollment
2 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, non small cell lung cancer